期刊
MOLECULAR CELL
卷 75, 期 4, 页码 669-+出版社
CELL PRESS
DOI: 10.1016/j.molcel.2019.05.036
关键词
-
资金
- Instituto de Salud Carlos III FEDER [PIE15/00008, PI16/00437]
- Generalitat de Catalunya [2017SGR135]
- Xarxa de Bancs de Tumors - Pla Director d'Oncologia de Catalunya (XBTC)
- FPI [BES-2014-068451]
- EMBO Short-Term Fellowship [na7084]
- European Union [702430]
- Francis Crick Institute - Cancer Research UK [FC0010048]
- UK Medical Research Council [FC0010048]
- Wellcome Trust [FC0010048]
- Wellcome Trust Senior Investigator Grant
- Instituto de Salud Carlos III from the Spanish government [PT13/0001]
- Spanish Ministry of Economy and Competitiveness
- Centro de Excelencia Severo Ochoa 2013-2017 [SEV-2012-0208]
- European Research Council (ERC) Advanced Investigator Grants (TelMetab)
- Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya [2014SGR678]
- Marie Curie Actions (MSCA) [702430] Funding Source: Marie Curie Actions (MSCA)
Phosphorylated IKK alpha(p45) is a nuclear active form of the IKK alpha kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-kappa B signaling. Insights into the sources of IKK alpha(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKK alpha(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKK alpha activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKK alpha or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKK alpha kinases in the DDR and reveal a combination strategy for cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据